Page 156 - CW E-Magazine (2-4-2024)

News from Abroad

EXPANSION
Schott Pharma plans new prefi llable syringe manu-

facturing facility in US

Schott Pharma, the German maker and expand the use of mRNA, GLP-1,
of pharmaceutical drug containment and other biologic therapies that require
solutions and delivery systems, will precise drug stability and storage pro-
build the fi rst US facility in Wilson, perties, Schott Pharma will be able to
North California, to manufacture pre- fi ll those orders quickly and effi ciently
fi llable polymer syringes required to here in the US. The impact of this faci-
meet the need for deep-cold storage lity will go far beyond local job creation
and transportation of mRNA medica- in North Carolina and will relieve stress
tions. In addition, the site will have the on the entire pharmaceutical industry
capability to produce glass prefi llable cines, vaccines, and other fi elds of supply chain,” said Mr. Andreas Reisse,
syringes for GLP-1 therapies, for applications, allowing Schott Pharma to CEO of Schott Pharma.
example to treat diseases such as dia- triple its contribution of glass and poly-
betes or obesity. The project, involving mer syringes to the US market by 2030. For over two decades, Schott Pharma
investment of $371-mn, is likely to see Bringing production to the US will has been manufacturing vials at its
groundbreaking by the end of 2024, reduce lead times and slash transpor- Lebanon, Pennsylvania (US), facility.
and operations starting in 2027. tation costs, as well as protect against Schott stated that even as it is not
future shortages of critical drugs and guaranteeing additional investment to
The new site will expand the US ensure pandemic preparedness. support other markets at this time, “the
supply chain for in-demand syringes site in Wilson offers the possibility of
that deliver lifesaving injectable medi- “As drug manufacturers develop future expansion.”
Johnson Matthey to sell Medical Device Components
business for $700-mn

UK’s Johnson Matthey (JM) has This brings the aggregate net proceeds Around $315-mn of the sale proceeds
agreed to sell 100% of its Medical from the divestment of value businesses will be returned to the company’s
Device Components (MDC) business to to signifi cantly more than our target shareholders, while the balance will be
London-based Montagu Private Equity of £300-m (around $380-mn),” said used to repay some existing debts and
for cash consideration of $700-mn on Mr. Liam Condon, CEO, Johnson Matthey. for other general corporate purposes.
a cash-free debt-free basis. The MDC
business produces components for ACQUISITION
medical device manufacturers globally IMCD boosts presence in Latin American
with a focus on precious metal alloys
and nitinol. The business serves a global food sector
customer base and operates manufac-
turing sites in the USA (San Diego), Dutch chemicals distributor, IMCD, leading speciality ingredients distributors
Mexico (Mexicali), and Australia has agreed to acquire 100% of the shares in Latin America for the food industry
(Tullamarine). of Bretano Costa Rica, S.A., Bretano El and supplies chemicals to construction
Salvador, S.A de C.V., Bretano Guate- and other industrial markets. Generating
“With our sale of MDC and a sepa- mala, S.A., and Grupo Bretano México, a revenue of approximately $48-mn in
rate sale of our battery systems business, S. de R.L. de C.V. (jointly Bretano). 2023, Bretano will add 101 employees
we have concluded the divestment pro- Established in 1961, Bretano is headquar- to IMCD throughout Latin America. In
gramme for our value businesses that tered in Costa Rica, with commercial and addition, Bretano adds a food applica-
was originally announced in May 2022 logistics operations in Mexico, Guate- tion laboratory, located in Costa Rica, to
as one of our key strategic objectives. mala and El Salvador. It is one of the IMCD’s global network of technical centres.

156 Chemical Weekly April 2, 2024

Contents Index to Advertisers Index to Products Advertised